Moderna battles Pfizer/Biontech to generate the first pivotal study data for a Covid-19 vaccine.
Pivotal data on finerenone might see it approved, but competing in the market will be trickier.
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
The pandemic remains the dominant storyline for drug stocks at the nine-month mark, with Vertex and Horizon rare non-Covid-related risers.
With the EU regulator already reviewing two coronavirus vaccines, could it beat the US FDA to the punch?
A few multi-billion-dollar deals got done in the third quarter, but 2020’s acquisition scene still looks anaemic.
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.